Kronos Bio, INC Form 4 insider transactions

A recent SEC Form 4 filing reveals that Kronos Bio, Inc. Director Katherine V. Stultz disposed of over 100,000 stock options as part of the company's acquisition by Concentra Biosciences, with options having an exercise price above the cash offer cancelled for no cash consideration.

Arie Belldegrun, a director of Kronos Bio, Inc., reported the disposition of over 3.4 million common shares and the cancellation of 122,600 stock options as a result of the company's acquisition by Concentra Biosciences.

Norbert W. Bischofberger, a Director and 10% Owner of Kronos Bio, Inc., has reported the disposition of all his common stock and employee stock options in the company following its acquisition by Concentra Biosciences, LLC.

Kronos Bio, Inc. Director Elena Ridloff has filed a Form 4 detailing the disposition of common stock and the cancellation of stock options as a direct result of the company's acquisition by Concentra Biosciences, LLC.

David M. Tanen, a Director of Kronos Bio, Inc., has reported the complete disposition of his direct and indirect common stock and stock option holdings in connection with the company's acquisition by Concentra Biosciences.

A recent SEC Form 4 filing reveals that Kronos Bio, Inc. Director Roshawn A. Blunt's stock options were cancelled without consideration as part of the company's acquisition by Concentra Biosciences, LLC.

A director of Kronos Bio, Inc. has reported the disposition of common stock and the cancellation of stock options as a result of the company's acquisition by Concentra Biosciences, LLC for $0.57 per share cash plus a contingent value right.

Kronos Bio, Inc. Director Joshua A. Kazam has reported the disposition of all his common stock and the cancellation of all stock options following the completion of the merger with Concentra Biosciences, LLC.

Deborah Knobelman, President and Interim CEO of Kronos Bio, Inc., has reported the disposition of all her common stock and employee stock options following the completion of the merger with Concentra Biosciences, LLC.

A recent SEC Form 4 filing reveals that Kronos Bio, Inc. Director Roger D. Dansey's stock options were cancelled as part of the company's acquisition by Concentra Biosciences, LLC, which included a tender offer of $0.57 per share cash plus a contingent value right.

Deborah Knobelman, President and Interim CEO of Kronos Bio, Inc., reported the sale of 24,838 shares of common stock on June 5, 2025, to satisfy estimated tax withholding obligations.

Allison Frisbee, Chief Administrative Officer of Kronos Bio, Inc., reports the acquisition of stock options.

Charles Y. Lin, Chief Scientific Officer of Kronos Bio, Inc., was granted employee stock options for 72,900 shares on October 15, 2024.

Norbert Bischofberger, the President and CEO of Kronos Bio, Inc., recently acquired additional shares of the company's common stock through multiple transactions.

Director Elena Ridloff reported the acquisition of stock options and common stock in Kronos Bio, Inc. on June 25, 2024.

Director Roger D. Dansey acquired 34,000 stock options in Kronos Bio, Inc. on June 25, 2024.

Katherine V Stultz, a director of Kronos Bio, Inc., acquired 34,000 stock options on June 25, 2024, exercisable for common stock.

Director Yang Taiyin acquired 34,000 stock options in Kronos Bio, Inc. on June 25, 2024.

Director Roshawn A. Blunt acquired 34,000 stock options in Kronos Bio, Inc. on June 25, 2024.

Director Joshua A Kazam acquired 34,000 stock options in Kronos Bio, Inc. on June 25, 2024.

Director Arie Belldegrun acquired 34,000 stock options in Kronos Bio, Inc. on June 25, 2024.

Director David M Tanen acquired 34,000 stock options in Kronos Bio, Inc. on June 25, 2024.

Norbert Bischofberger, CEO of Kronos Bio, recently acquired a significant number of common stock shares through a series of transactions.

Deborah Knobelman, CFO of Kronos Bio, Inc., reports acquiring 164,260 shares of common stock and 246,390 employee stock options on June 3, 2024.